Community Practice Connections™: Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is an aggressive disease. There is a need for continued clinical development of treatment for newly diagnosed and relapsed/refractory (R/R) DLBCL. In the past few years, several novel agents have been approved by the FDA to treat patients with R/R DLBCL, with many more therapies under investigation. The constant emergence of new treatment options is shifting the landscape for clinicians who manage patients with DLBCL. As clinical trials continue to accumulate data, clinicians must consider these results for appropriate patient recruitment into clinical trials and preemptively contemplate how the reported data may change best practice for R/R DLBCL.

This Community Practice Connection™ program will provide an opportunity for clinicians to participate in an online series of video interviews with top experts in DLBCL on current strategies to assess risk, clinical outcomes related to first-line standards of care, exploration of unmet treatment needs for patients with R/R DLBCL, and frontline data pertaining to treatment of transplant-ineligible patients with R/R DLBCL.

Benefits of Participating

• See how top experts assess risk and manage patients with DLBCL
• Gain expert insights into treatment of transplant-ineligible patients with R/R DLBCL
• Develop strategies to manage therapy-related adverse events
• Learn about emerging agents for patients with R/R DLBCL

Acknowledgement of Commercial Support

This activity is supported by an educational grant from MorphoSys AG.

Target Audience

This educational activity is directed toward medical oncologists/hematologists, nurse practitioners, nurses, and fellows who treat patients with DLBCL. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of DLBCL are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Describe current standards of care and outcomes for patients with DLBCL
• Summarize unmet clinical needs and methods to assess risk in patients with DLBCL
• Explain novel mechanisms of action and therapeutic targets for patients with newly diagnosed or relapsed/refractory DLBCL
• Evaluate the efficacy and adverse event profile of emerging approaches for patients with relapsed/refractory DLBCL

Faculty, Staff, and Planners’ Disclosures

Faculty

Gilles A. Salles, MD, PhD
Professor of Medicine and Hematology
Claude Bernard University of Lyon
Head of the Department of Hematology
Lyon-Sud University Hospital Complex
Pierre-Bénite, France

Disclosures: Consultant: AbbVie Inc, Amgen, Autolus Therapeutics, Celgene, Epizyme, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, MorphoSys AG, Novartis, Roche, Servier Laboratories, Takeda Pharmaceutical Company

Ranjana Advani, MD
Saul Rosenberg Professor of Lymphoma
Stanford Cancer Institute
Stanford, CA

Disclosures: Other: Investigational: magrolimab, Accibrukicks, MOR, P13K inhibitor, BI7E

Kami J. Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH

Disclosures: Grant Research Support: Bristol-Myers Squibb; Consultant: AstraZeneca, Celgene, Pharmacyclics LLC, Teva Pharmaceutical Industries

Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Bristol-Myers Squibb; Curis, Inc; Janssen Pharmaceuticals; Merck & Co, Inc; Roche; Syndax Pharmaceuticals Inc.; Consultant: Bio-Path Holdings, Celgene, Epizyme, HCM, Roche, Xynomic Pharma; Other: Honorarium: AbbVie Inc; Curis, Inc; Epizyme; Janssen Pharmaceuticals; Merck & Co, Inc; Roche; Takeda Pharmaceutical Company

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER^® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.